NASDAQ:VTL - Vital Therapies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.21 -0.01 (-4.55 %) (As of 02/19/2019 04:00 PM ET)Previous Close$0.22Today's Range$0.21 - $0.2252-Week Range$0.15 - $9.75Volume10,592 shsAverage Volume1.17 million shsMarket Capitalization$8.90 millionP/E Ratio-0.16Dividend YieldN/ABeta3.54 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vital Therapies, Inc., a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California. Receive VTL News and Ratings via Email Sign-up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTL Previous Symbol CUSIPN/A Webvitaltherapies.com Phone858-673-6840Debt Debt-to-Equity RatioN/A Current Ratio3.35 Quick Ratio3.35Price-To-Earnings Trailing P/E Ratio-0.16 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book0.18Profitability EPS (Most Recent Fiscal Year)($1.31) Net Income$-52,070,000.00 Net MarginsN/A Return on Equity-167.46% Return on Assets-132.21%Miscellaneous Employees97 Outstanding Shares42,370,000Market Cap$8.90 million OptionableOptionable Vital Therapies (NASDAQ:VTL) Frequently Asked Questions What is Vital Therapies' stock symbol? Vital Therapies trades on the NASDAQ under the ticker symbol "VTL." How were Vital Therapies' earnings last quarter? Vital Therapies Inc (NASDAQ:VTL) announced its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. View Vital Therapies' Earnings History. When is Vital Therapies' next earnings date? Vital Therapies is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Vital Therapies. What price target have analysts set for VTL? 4 equities research analysts have issued 1-year target prices for Vital Therapies' stock. Their forecasts range from $6.00 to $18.00. On average, they anticipate Vital Therapies' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 5,614.3% from the stock's current price. View Analyst Price Targets for Vital Therapies. What is the consensus analysts' recommendation for Vital Therapies? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vital Therapies in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vital Therapies. What are Wall Street analysts saying about Vital Therapies stock? Here are some recent quotes from research analysts about Vital Therapies stock: 1. According to Zacks Investment Research, "Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. " (11/17/2018) 2. Cantor Fitzgerald analysts commented, ": We are downgrading our rating on VTL shares from and establishing a new PT of $0.50 from $18. We had believed learnings from a post-hoc analysis of the VTL-208 Phase 2 study that were incorporated into the VTL-308 trial design could bias the outcome in a positive way. VTL has provided no specific details of the VTL-308 results, but disclosure that the trial failed to meet the primary and secondary endpoints and that development would cease is adequately informative. The company also announced that it would pursue strategic options, which we suppose could include a merger with a company seeking a U.S. public listing." (9/12/2018) 3. BTIG Research analysts commented, "Q2 earnings call revolved around the upcoming topline data from its VTL-308 trial in severe alcoholic hepatitis (sAH). The data set is expected to be locked soon and topline data will be press released in the back half of September, with a conference call to follow. We see the announcement as a binary event. Although the insights discussed during May’s R&D Day left us with a better understanding of how ELAD should work, we remain cautious. With VTL-308 targeting patients who fit specific enrollment criteria that seems more likely to show a survival benefit, we see the likelihood of positive data as better than even, but nowhere near a shoo-in (perhaps 65-35)." (8/9/2018) Has Vital Therapies been receiving favorable news coverage? Headlines about VTL stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Vital Therapies earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are some of Vital Therapies' key competitors? Some companies that are related to Vital Therapies include Agile Therapeutics (AGRX), Lipocine (LPCN), Oncolytics Biotech (ONCY), ContraFect (CFRX), ProPhase Labs (PRPH), Oncomed Pharmaceuticals (OMED), Neurotrope (NTRP), Heat Biologics (HTBX), Addex Therapeutics (ADDXF), Sophiris Bio (SPHS), Catabasis Pharmaceuticals (CATB), Novan (NOVN), Adial Pharmaceuticals (ADIL), AzurRx BioPharma (AZRX) and Akari Therapeutics (AKTX). Who are Vital Therapies' key executives? Vital Therapies' management team includes the folowing people: Dr. Duane D. Nash, CEO, Pres & Director (Age 48)Mr. Robert A. Ashley, Exec. VP & CTO (Age 61)Mr. Michael V. Swanson M.B.A, CFO, Exec. VP & Teasurer (Age 64)Mr. John M. Dunn, Gen. Counsel & Sec. (Age 67)Dr. Peter Linden M.D., Clinical Investigator Who are Vital Therapies' major shareholders? Vital Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.41%), Geode Capital Management LLC (1.61%), Virtu Financial LLC (0.73%), Two Sigma Investments LP (0.49%) and SG Americas Securities LLC (0.47%). Company insiders that own Vital Therapies stock include Cheryl Cohen, Douglas Evan Godshall, Duane Nash, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Institutional Ownership Trends for Vital Therapies. Which major investors are selling Vital Therapies stock? VTL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have sold Vital Therapies company stock in the last year include Cheryl Cohen, Douglas Evan Godshall, Jean Jacques Bienaime and Muneer A Satter. View Insider Buying and Selling for Vital Therapies. Which major investors are buying Vital Therapies stock? VTL stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, SG Americas Securities LLC, Virtu Financial LLC and Two Sigma Investments LP. Company insiders that have bought Vital Therapies stock in the last two years include Duane Nash, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Insider Buying and Selling for Vital Therapies. How do I buy shares of Vital Therapies? Shares of VTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vital Therapies' stock price today? One share of VTL stock can currently be purchased for approximately $0.21. How big of a company is Vital Therapies? Vital Therapies has a market capitalization of $8.90 million. The company earns $-52,070,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Vital Therapies employs 97 workers across the globe. What is Vital Therapies' official website? The official website for Vital Therapies is http://vitaltherapies.com. How can I contact Vital Therapies? Vital Therapies' mailing address is 15010 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected] MarketBeat Community Rating for Vital Therapies (NASDAQ VTL)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 252 (Vote Outperform)Underperform Votes: 201 (Vote Underperform)Total Votes: 453MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe VTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?